# of Displayed Technologies: 2 / 2


Categories

Clinical Stage EAAT2 Activator LH-001 for Treatment of Alzheimer’s Disease, ALS and Epilepsy
TS-075262 — PROBLEM Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking, affecting 6–7 million people in the U.S. and over 50 million worldwide. There is currently no cure, and available treatments only temporarily manage symptoms or modestly slow disease progressi…
  • College: College of Medicine (COM)
  • Inventors: Lin, Chien-Liang
  • Licensing Officer: Schworer, Adam

Translational Activators of the Glutamate Transporter EAAT2 to Treat Neurological and Psychiatric Diseases
TS-043938 — Small molecule technology with novel translational activation mechanism.
Glutamate is a major neurotransmitter in the mammalian central nervous system (CNS) and essential for normal brain function including cognition, memory, and learning. However, the extracellular concentration of glutamate must remain below excitotoxic levels (~ 1 μM) to avoid overstimulation of …
  • College: College of Medicine (COM)
  • Inventors: Lin, Chien-Liang
  • Licensing Officer: Schworer, Adam

Loading icon